Business News

Sandoz bets big on biosimilars, aims to double group sales by 2035

FinSiddhi

Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfolio to 100 drugs by 2040. Sandoz targets mid-to-high single-digit sales growth from 2025 to 2030. Its net sales targets exclude potential contributions from generic GLP-1 drugs. Sandoz will invest an additional $300 million in a Slovenian biosimilar manufacturing facility.
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.

Related Posts

In the 1980s, ferrets were released on Northern Ireland’s Rathlin Island to control rabbits; decades later, they threatened seabirds at a colony of more than 250,000 birds

Ferrets introduced in the 1980s to control rabbits became a significant threat to Rathlin Island’s seabirds. Conservationists launched a five-year project to remove these invasive predators from the island. Using advanced techniques, teams worked to eradicate ferrets and brown rats from the island. Rathlin Island was declared ferret-free in March 2026 after extensive eradication efforts….